Drugs in MeSH Category Vitamins

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes
Amneal Pharms	CALCITRIOL	calcitriol	CAPSULE;ORAL	203289-001	Jun 14, 2017	AB	RX	No	No
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes			Y

Market dynamics and patent landscape for drugs in NLM MeSH Class: Vitamins

Last updated: May 22, 2026

Executive summary

MeSH Class “Vitamins” covers a high-volume, low-to-mid pricing segment where patent position typically depends on (1) formulation and delivery system patents, (2) method-of-use and dose-regimen patents, and (3) “new salt/ester/isomer” product generations rather than primary API discovery. Across the category, exclusivity and brand moat are most durable where vitamin combinations are co-formulated with specific actives, where controlled-release or bioavailability claims exist, or where the product is supported by sizable RCT-like clinical packages that anchor method-of-use. Competition is increasingly shaped by Orange Book-dense generic entry pressure for single-ingredient vitamins and bioequivalent “workalike” dynamics for combination and specialty delivery forms. Patent estates are usually fragmented across dosage strengths and NDC-specific formulations, creating uneven generic launch risk within the same brand line.

What patents protect vitamin drugs and supplements in MeSH “Vitamins”?

Featured snippet answer: In vitamins, protection is most often concentrated in formulation, combination, controlled release, and method-of-use claims rather than in the underlying vitamin chemistry.

How vitamin patent estates are structured

1. Formulation patents

   • Controlled-release matrices (polymer coatings, diffusion barriers, osmotic pumps)
   • Bioavailability enhancers (complexation, solubilizers, particle engineering)
   • Stabilization systems (oxygen/moisture/heat protection, chelation chemistry)

2. Combination patents

   • Fixed-dose combinations (FDC) for specific deficiency panels or clinical regimens
   • Ratios and timing of multiple vitamins (e.g., co-dosed fat-soluble vitamins with minerals)

3. Method-of-use patents

   • Targeted regimens (dosage, frequency, titration)
   • Indications that map to clinical outcomes and dosing strategy

4. API “new form” patents (API lifecycle)

   • Isomers, salts, stereochemical variants, hydrates, co-crystals
   • Prodrug-like derivatives for solubility or absorption

5. Manufacturing patents

   • Particle size control, coating process, granulation/embedding methods
   • Scale-up constraints that can function as non-therapeutic “process barriers” in litigation

Which patent types are most likely to delay generic entry?

• Controlled-release and specialty delivery: often litigated because bioequivalence may require comparable release profiles.
• Complex vitamin combinations: generics face dosing-ratio constraints tied to claims.
• Method-of-use: may limit launch if clinical use is essential to the brand’s labeled claims.

What matters for litigation strategy in vitamins?

• Claim-by-claim mapping: vitamins have numerous strengths and excipient compositions.
• Formulation carve-outs: generic formulations can sometimes avoid infringement by changing release kinetics or excipient systems.
• Orange Book scope: patents are often listed per product, strength, and sometimes per NDC.

When does vitamin exclusivity and patent term end?

Featured snippet answer: For vitamin brands, exclusivity commonly ends via standard patent expiration and shorter, product-specific regulatory exclusivities (where applicable). The practical launch window is determined by Orange Book patent listings per NDC and any Paragraph IV challenges tied to those listings.

Typical exclusivity timelines (category-level pattern)

• Patent expiration: controls the bulk of brand protection for “prescription vitamin” products once composition and formulation patents expire.
• Regulatory exclusivity (where applicable): can extend protection beyond patent term, but vitamins often see limited reliance on long-term exclusivities compared with biologics or novel small molecules.
• Pediatric exclusivity: may apply for selected brands after pediatric study completion.
• New chemical entity and new molecular entity exclusivity: less common for “vitamin” because many actives predate modern exclusivity frameworks.

Generic entry risk clock

• Orange Book listing density and age distribution drive the “last patent standing” profile.
• If the brand has multiple formulation patents, generic launch can be delayed while later patents are litigated or removed via settlement.
• If only older formulation patents are listed for key strengths, generic entry tends to compress into a narrow post-expiration window.

What triggers earlier generic launch?

• Patent non-listing or listing gaps: absence of specific formulation patents for an NDC can enable “skinny” generic pathways.
• Design-around feasibility: generics can switch controlled-release mechanisms or excipient systems if the claims are narrow.
• Label carve-outs: generics can launch for non-patented strengths or narrower indications.

What patents are listed in the Orange Book for vitamin products?

Featured snippet answer: Orange Book listings for vitamins usually include formulation patents and, less frequently, method-of-use patents. Coverage often varies by strength and by dosage form.

Orange Book listing patterns that drive freedom-to-operate

• Same brand, multiple NDCs: each strength may have distinct formulation and process patents.
• Succession of filings: later additions often focus on stability and bioavailability, increasing the number of listed patents close to launch.
• Patent thickets: brands sometimes list multiple continuation filings to cover different aspects of a composition or coating.

How to read Orange Book listings for vitamins (operational view)

• Identify “key” listed patents tied to:
  • therapeutic claim scope (method-of-use),
  • dosage form performance (controlled release),
  • and AB-rating equivalence exposure (bioavailability/performance claims).
• Map each listed patent to expected generic design changes:
  • release kinetics,
  • coating composition,
  • particle size and granulation,
  • and stability-related composition constraints.

How many patents cover top vitamin brands and what is the strength profile?

Featured snippet answer: Vitamin brands typically have a modest-to-medium number of listed patents per NDC, but the strength profile concentrates in formulation claims. The estate strength is highest where (1) the core release system is claimed, (2) there is robust clinical and stability data, and (3) claims are not easily designed around.

Category-level strength characteristics

• Narrow formulation claims: reduce injunction risk but still create settlement leverage.
• Broad formulation claims: increase litigation risk for generics but can be weakened by prior art in older vitamin chemistry.
• Process patents: sometimes weak in litigation if claims read broadly and are hard to prove infringement.

What to expect from prior art dynamics

• Vitamins have long publication histories. Patent novelty often hinges on delivery system engineering, combination ratios, and specific stabilization chemistries rather than core chemistry.
• Patent validity challenges frequently target obviousness based on prior formulation technologies and established excipient choices.

Which vitamin companies face Paragraph IV challenges and generic entry?

Featured snippet answer: Competitive pressure tends to concentrate among manufacturers holding branded prescription vitamins and those marketing line-extensions with the richest Orange Book listings. Generic entry typically follows where (1) the brand has mature patents and (2) the generic can design around controlled-release constraints.

Generic entry playbooks in vitamins

• “Bottle-and-bottle” strategy: enter the most used strengths first if patent coverage is weakest there.
• Formulation design-around: change release system or manufacturing process while retaining dissolution and exposure equivalence.
• Label alignment: limit claim overlap by not seeking the same method-of-use label where possible.

Where challenges are most likely

• Controlled-release vitamins
• Narrowly specified FDC products with clinical dosing rationales
• High-volume deficiency treatment lines where physician prescribing supports brand durability until patent expiry

What vitamin formulations are protected by patents?

Featured snippet answer: Patent coverage for vitamin formulations usually targets controlled release, improved absorption, stability, and fixed-dose combinations with clinically specific ratios.

Formulation subcategories with frequent patent activity

• Controlled-release and delayed-release
  • oxy/matrix systems, beads, multi-particulate release, enteric coatings
• Improved bioavailability systems
  • complexes or encapsulation to address solubility limitations
• Stability and shelf-life systems
  • anti-oxidants, oxygen scavengers, moisture barrier packaging materials paired with formulation claims
• Combination products
  • FDC ratio constraints and sequential dosing logic

Dose-form variability that affects patent scope

• Tablet vs capsule: distinct release and coating claims
• Immediate vs extended release: separate formulation claims even for the same active set
• Pediatric chewables and effervescents: distinct manufacturing and excipient systems

How do method-of-use patents affect vitamin prescribing and labeling?

Featured snippet answer: Method-of-use patents in vitamins matter most where labels encode dosing regimens linked to clinical outcomes. They can force generics to omit certain indications or to narrow labeling while they litigate.

Common method-of-use claim themes

• Dosing regimen specifics: frequency, titration, and duration
• Clinical settings: deficiency syndromes with risk profiles
• Outcome-linked language: reduced biomarkers or improved clinical endpoints tied to dosing strategy

Litigation mechanics

• Method-of-use infringement depends on label-aligned prescribing practices.
• Generics may use “carve-out” labeling strategies to avoid infringement, reducing damages exposure but potentially weakening market attractiveness.

What patent litigation affects vitamin products?

Featured snippet answer: Litigation is typically driven by formulation patents and controlled-release claims, with settlements often enabling staggered generic launches by strength and dosage form.

Litigation outcomes that shape market dynamics

• Narrow settlements: allow entry for certain strengths with modified formulations.
• Strength-specific injunction leverage: brands use remaining listed patents to protect the highest-revenue SKUs.
• Dismissal and covenant outcomes: generic launches proceed but with design constraints.

How settlements are structured in vitamins (pattern-level)

• Generic launch date windows per strength
• Label carve-outs that avoid method-of-use infringement
• Agreement terms on manufacturing processes or formulation similarities

What is the biosimilar risk for vitamins?

Featured snippet answer: Biosimilar frameworks do not apply because vitamins are small-molecule products, not biologics. The relevant competitive risk is generic and “authorized generic” pressure under FDA small-molecule pathways.

How does vitamin patent coverage differ across the FDA pathway: NDA vs ANDA?

Featured snippet answer: Vitamins in practice are usually authorized via NDAs and then challenged via ANDAs, with the Orange Book defining listing-based entry barriers.

Operational distinction

• NDA holder: maintains brand protection via composition, formulation, and listed patents.
• ANDA filer: must address Orange Book patents with Paragraph IV, Paragraph III, or other statutory certifications.
• The Orange Book drives whether “skinny label” or full-label equivalence is available.

What generic entry risks exist for prescription vitamins?

Featured snippet answer: Generic entry risk is highest where (1) Orange Book coverage is thin for controlled-release performance and (2) the brand’s most recent patents do not extend beyond the key strength expiry dates.

Risk factors by product design

• Controlled-release complexity: reduces generic feasibility; increases likelihood of litigation.
• Single-ingredient immediate release: higher probability of rapid generic availability post-expiration.
• Complex FDC ratios: increased design-around complexity and higher chance of patent-protected entry delays.

Business impact drivers

• Revenue concentration in top SKUs: remaining patent coverage for those SKUs determines the post-expiration runway.
• Payer and formulary behavior: if substitution is easy, generic uptake is faster.
• Physician prescribing patterns: can slow early switching even when generic exists.

Commercial comparison: how do patent estates translate into pricing and market share?

Featured snippet answer: Vitamin brand pricing and share durability correlate with (1) how difficult the branded formulation is to replicate and (2) how many Orange Book patents remain listed for the highest-volume NDCs.

Revenue exposure map (category-level)

• Highest exposure SKUs
  • extended-release and controlled-release variants
  • high-usage deficiency and clinical regimen products
• Lower exposure SKUs
  • legacy immediate-release formats with fewer active formulation patents
  • strengths with limited market share or less detailed formulation patent coverage

Pricing dynamics

• When generic entry is easy, brands often see price compression and market-share migration.
• When controlled-release replication is difficult, brands can maintain premium pricing longer or trade off with settlements that delay direct competition.

Key Takeaways

• Vitamin patent protection is typically formulation- and combination-driven, with controlled release and stability claims doing the heavy lifting.
• Exclusivity and patent expiry create a launch “cliff” that is best predicted by Orange Book listings per NDC, not by the underlying vitamin chemistry.
• Generic threats under ANDA are driven by whether a generic can design around controlled-release performance claims and by strength-specific patent coverage.
• Method-of-use patents can force labeling carve-outs and shape early generic adoption even when chemical equivalence is straightforward.
• Litigation in vitamins usually centers on formulation infringement and settlement terms that control entry by strength and dosage form.

FAQs

1. How do Orange Book patent listings for prescription vitamins differ by strength and dosage form?
2. What is the most common design-around strategy for controlled-release vitamin patents in ANDA filings?
3. Do vitamins have meaningful pediatric exclusivity impacts on generic entry timing under FDA rules?
4. How do method-of-use patents change “skinny label” opportunities for generic vitamin manufacturers?
5. What manufacturing process claims most often drive vitamin formulation litigation and settlement leverage?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA database).
2. U.S. Food and Drug Administration. Hatch-Waxman Act framework for ANDAs and patent certifications (FDA guidance and related materials).
3. National Library of Medicine. Medical Subject Headings (MeSH) Browser: Vitamins. (NLM database).